galectin therapeutics nasdaq galt home about galectin our team our pipeline news investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs contact us news galectin therapeutics to present at the singular research summer conference july    press release patent for reducing inflammatory response granted to galectin therapeutics june    press release galectin therapeutics announces important milestones towards completion of nash cx trial june    press release read more videos why did you choose to become the ceo of galectin therapeutics are you conducting clinical trials with grmd what results have you seen so far can you give me a quick overview of galectin therapeutics and the opportunity it sees for grmd why are the results of the grmd psoriasis study so promising why is the nashcx trial so important see all videos galectin therapeutics inc nasdaq galt financial tear sheetfilings  reports stock price updates every  minutes corporate snapshot latest corporate presentation media fact sheet corporate fact sheet subscribe   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information ceo perspectives with dr peter traber of galectin therapeutics about peter g traber md dr peter traber is the president chief executive officer and chief medical officer of galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer about galectin therapeutics nasdaq galt galectin therapeutics is a biotechnology company focused on discovery and development we apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer search search for latest ceo perspectives ceo perspectives is the official blog of dr peter traber president ceo and cmo of galectin therapeutics nasdaq galt ceo perspectives offers timely insight on galectin therapeutics’ company news and industry trends affecting the treatment of nash nonalcoholic steatohepatitis and use of galectin inhibitors galectin therapeutics nasdaq galt home about galectin our team our pipeline news investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs contact us about us leadership board of directors scientific advisory board clinical advisory board careers about us home » who we are » about us galectin therapeutics is a biotechnology company focused on discovery and development we apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer drug candidates based on our unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function galectin therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory fibrotic and malignant diseases we focus on diseases with serious lifethreatening consequences to patients and those where current treatment options are limited our strategy is to establish clinical development approaches that add value to the company in the shortest time possible and to seek partners as the program advances and requires much greater resources galectin therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development the lead development program is in nonalcoholic steatohepatitis nash with cirrhosis the most advanced form of nash related fibrosis this is the most common liver disease and one of the largest drug development opportunities available today additional development programs are in treatment of severe atopic dermatitis moderatetosevere plaque psoriasis and in combination immunotherapy for advanced melanoma and other malignancies   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information galectin therapeutics nasdaq galt home about galectin our team our pipeline news investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs contact us about us leadership board of directors scientific advisory board clinical advisory board careers leadership home » who we are » leadership peter g traber md president chief executive officer and chief medical officer harold h shlevin phd chief operating officer and corporate secretary jack w callicutt cpa chief financial officer rex horton executive director of regulatory affairs and quality assurance adam e allgood pharmd rph executive director of clinical development eliezer zomer phd vice president discovery research and product development peter g traber md president chief executive officer and chief medical officer dr traber is president emeritus of baylor college of medicine where he was chief executive officer from  to  from  to  he was senior vice president of clinical development and medical affairs and chief medical officer of glaxosmithkline plc dr traber served as chief executive officer of the university of pennsylvania health system and was chair of the department of internal medicine and chief of gastroenterology for the university of pennsylvania school of medicine dr traber has also managed a molecular biology research laboratory and published over  articles of original research reviews and book chapters dr traber received his md from wayne state school of medicine a bs in chemical engineering from the university of michigan and a certificate in medical leadership from wharton business school harold h shlevin phd chief operating officer and corporate secretary dr shlevin is a bioscience industry executive with  years of senior management experience in the development and commercialization of pharmaceuticals diagnostics and vaccines before joining galectin therapeutics dr shlevin led georgia institute of technology’s advanced technology development center atdc as principal and manager of bioscience commercialization efforts where he served as a catalyst for new bioscience startup companies his leadership roles have included president and chief executive officer of solvay pharmaceuticals where he oversaw the successful launch of the first topical testosterone gel product in the us cofounder of ciba vision ophthalmics a specialty ophthalmic drug company where he headed efforts leading to the approval of the first nonsteroidal agent for treatment of ocular inflammation and several other drug products founder president and chief executive officer of tikvah therapeutics a company focused on clinical development of therapeutics for treatment of neurological diseases and vice president and head of operations and commercial development for altea therapeutics corporation a clinicalstage drug delivery company with platform technology applicable to the transdermal delivery of biologics dr shlevin earned his ba from boston university and ms and phd in physiology from the university of rochester medical school he completed postdoctoral training in pharmacology at mayo clinic where he subsequently served as assistant professor of pharmacology and physiology he is a member of scientific and business societies including the institute of electrical and electronics engineers licensing executives society american physiological society american society of pharmacology and experimental therapeutics and is an inventor on several issued and pending patents dr shlevin currently serves on the board of directors of cardiome pharma corp nasdaqcrme and as an advisor to clearside biomedical inc jack w callicutt cpa chief financial officer mr callicutt has over  years of public and private company experience including more than a decade of audit tax and sec registrant experience with a major accounting firm he was most recently chief financial officer for reach health inc a telemedicine firm where he completed a  million private placement previous positions include chief financial officer of vystar corporation a public medical device company whose latex products are devoid of antigenic proteins where he led all areas of financial reporting accounting treasury risk management and administration and secured over  million in financing previous experiences also include chief financial officer roles at private companies including ivox and tikvah therapeutics and at coratus genetics a publiclytraded biopharmaceutical company mr callicutt is a certified public accountant and graduated cum laude with a bba degree in accounting and computer science from delta state university rex horton executive director of regulatory affairs and quality assurance mr horton is an experienced industry professional with  years of management and leadership experience in global regulatory affairs matters including drugs biologics and vaccines he has broad range of regulatory affairs and quality leadership experience that is directly relevant to galectin therapeutics’ development programs with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas including gastroenterology he was most recently was director of regulatory affairs at chelsea therapeutics where he successfully led the organization through its first nda filing and favorable fda advisory committee meeting in past leadership roles at solvay pharmaceuticals and abbott laboratories he led approval efforts for key products including androgel® stickpack creon® capsules and luvox® cr capsules he has also provided chemistry manufacturing and controls cmc regulatory leadership and support of inds and ndas including estrogel® and androgel® pump mr horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by solvay in its interactions with the fda he earned his bachelor’s degree in industrialmanufacturing and systems engineering from the georgia institute of technology he is a member of the regulatory affairs professional society raps drug information association dia and american association of pharmaceutical scientists aaps adam e allgood pharmd rph executive director of clinical development dr allgood is an experienced industry professional with more than  years of pharmaceutical industry experience in effectively designing implementing monitoring and directing clinical programs in all four phases of clinical development ranging from phase  firstinhuman trials to large global phase  clinical trials and post marketing trials his therapeutic expertise spans a variety of therapeutic areas including gastroenterology and encompasses clinical trial leadership key opinion leader interface significant contract research organization management experience clinical trial investigator training and clinical advisory board responsibilities in addition dr allgood has extensive clinical research andor regulatory experience in immunology rheumatology neurology and women’s health dr allgood most recently was associate director of global pharmaceutical regulatory affairs at ucb inc a multinational biopharmaceutical company his prior positions include leadership roles at abbott laboratories and solvay pharmaceuticals in regulatory affairs clinical development and medical affairs dr allgood earned his doctor of pharmacy pharmd degree summa cum laude from mercer university college of pharmacy and health sciences in atlanta and is a registered pharmacist rph he is a member of the american pharmacists association apha the georgia pharmacy association gpha and the association of the united states army ausa eliezer zomer phd vice president discovery research and product development dr zomer is the founder of alicon biological control where he served from  to  he was vice president of product development at safescience inc from  to  and from  to  was vice president of research and development at charm sciences inc dr zomer received a bsc degree in industrial microbiology from the university of tel aviv a phd in biochemistry from the university of massachusetts in  and completed his postdoctoral study at the national institutes of health   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information board of directors  galectin therapeutics inc contact us investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs newsroom home who we are what we do who we help overview press releases events  presentations corporate governance management board of directors committee composition financial information stock information faqs email alert subscription board of directors home » investor relations » corporate governance » board of directors marc rubin md chairman of the board since january  lead director from may  to january  director since october  dr rubin is executive chairman of the board of directors of titan pharmaceuticals inc ttnp otc bb and served as its president and chief executive officer from october  to january  until february  dr rubin served as head of global research and development for bayer schering pharma as well as a member of the executive committee of bayer healthcare and the board of management of bayer schering pharma prior to the merger of bayer pharmaceuticals and schering ag in june  dr rubin was a member of the executive board of schering ag since joining the company in october  as well as chairman of schering berlin inc and president of berlex pharmaceuticals a division of schering ag from  until august  dr rubin was employed by glaxosmithkline where he held positions of responsibility in global clinical and commercial development overseeing programs in the united states europe asia and latin america from  through  at glaxosmithkline he was senior vice president of global clinical pharmacology  discovery medicine dr rubin holds an md from cornell university medical college and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases dr rubin is a member of the board of directors of curis inc nasdaq cris and formerly served on the board of directors of medarex inc now a subsidiary of bristolmyers squibb company member of the compensation committee member of the nominating and governance committee gilbert f amelio phd director since february  mr amelio began his career at bell labs in murray hill new jersey since january   dr amelio has provided consulting and advisory services through gfa llc a california limited liability company he was a senior partner of sienna ventures a privatelyheld venture capital firm in sausalito california from april  until the fund closed per plan on december   dr amelio was chairman and chief executive officer of jazz technologies inc now a wholly owned subsidiary of tower semiconductor ltd an independent specialty wafer foundry from august  until his retirement in september  when he was named chairman emeritus dr amelio was chairman and chief executive officer of beneventure capital llc a fullservice venture capital firm in san francisco california from  to  and was principal of aircraft ventures llc a consulting firm in newport beach california from april  to december  dr amelio was elected a director of att in february  and had previously served as an advisory director of att then known as sbc communications inc from april  to february  he served as a director of pacific telesis group from  until the company was acquired by att in  prior to  he served as chairman president and ceo of national semiconductor  and apple computer  member of the compensation committee chair of the nominating and governance committee james c czirr director since february  executive chairman from february  to january  cofounder in  mr czirr is a cofounder of x fund lp and is a managing member of x capital management llc the general partner of x fund lp mr czirr was a cofounder of galectin therapeutics in july  mr czirr was instrumental in the early stage development of safe science inc a developer of anticancer drugs served from  to  as chief executive officer of minerva biotechnologies corporation a developer of nano particle bio chips to determine the cause of solid tumors and was a consultant to metalline mining company inc now known as silver bull resources inc amex svbl a mineral exploration company seeking to become a low cost producer of zinc mr czirr received a bba degree from the university of michigan member of the irpr committee kevin d freeman cfa director since may  mr freeman holds the chartered financial analyst designation and is chief executive officer of cross consulting and services llc an investment advisory and consulting firm founded in  he is also author of a new york times bestselling book about the stock market and economy formerly he was chairman of separate account solutions inc and held several offices at franklin templeton investment services from  to  he holds a bs in business administration from university of tulsa tulsa oklahoma member of the audit committee arthur r greenberg director since august  mr greenberg has more than  years in the semiconductor equipment and materials industries he is the president founder and owner of prism technologies inc since  which provides professional sales and marketing services as well as business development and consulting services mr greenberg is a member of the board of uv tech systems a designer and manufacturer of equipment used to fabricate semiconductor devices previously he has been a founder of several successful companies in silicon valley and was the first president of semi north america a semiconductor equipment and materials industry trade association representing the interests including public policy of all semi members doing business in north america mr greenberg is also a member of the advisory board of the salvation army of santa clara county mr greenberg received his bsba degree in business administration from henderson state university member of the audit committee member of the irpr committee john mauldin director since may  mr mauldin is president of millennium wave advisors llc an investment advisory firm founded in  and a registered representative of millennium wave securities llc a finra registered brokerdealer which was founded in  previously he was chief executive officer of the american bureau of economic research he has many publications on investments and financial topics including a new york times bestseller and articles in the financial times and the daily reckoning and has been a frequent guest on cnbc yahoo tech ticker and bloomberg tv he holds a ba from rice university and a mdiv from southwestern baptist theological seminary member of the nominating and governance committee since  gilbert s omenn md phd director since september  dr omenn is a director of amgen inc and armune biosciences inc he is a professor of internal medicine human genetics and public health and director of the center for computational medicine and bioinformatics at the university of michigan he leads major research programs in proteomics and integrative biomedical informatics dr omenn served as executive vice president for medical affairs and as chief executive officer of the university of michigan health system from  to  earlier he was the dean of the school of public health and community medicine and professor of medicine at the university of washington dr omenn is the author of more than  research papers and scientific reviews and authoreditor of  books he received the john w gardner legacy of leadership award from the white house fellows association in  and the walsh mcdermott award from the institute of medicine in  he is vice president of the international human proteome organization dr omenn received his ba summa cum laude from princeton university md magna cum laude from harvard medical school and phd in genetics from the university of washington chair of the compensation committee steven prelack director since april  mr prelack is the currently senior vice president and chief operating officer of vetcor which owns and operates  veterinary hospitals across the country mr prelack has held that position since may  previously from  he was senior vice president chief financial officer and treasurer of velquest corporation a provider of automated compliance software solutions for the pharmaceutical industry in this capacity mr prelack oversaw sales business development operations and finance mr prelack is also a director of codeco corporation a designer and manufacturer of custom resisters and switches mr prelack served as director and audit committee chair for biovex from  through  mr prelack a certified public accountant received a bba degree from the university of massachusetts at amherst in  and is a member of the national association of corporate directors chair of the audit committee peter g traber md director since february  dr traber is president emeritus of baylor college of medicine and from  to  was president and chief executive officer from  to  he was senior vice president clinical development and medical affairs and chief medical officer of glaxosmithkline plc dr traber was the chairman of the board and chief executive officer of terrasep llc a mountain view california biotechnology company he also has served as chief executive officer of the university of pennsylvania health system as well as chair of the department of internal medicine and chief of gastroenterology for the university of pennsylvania school of medicine dr traber received his md from wayne state school of medicine and a bs in chemical engineering from the university of michigan theodore zucconi phd director since  theodore zucconi phd served in roles of president ceo and business development director of galectin therapeutics at various times from september  through may  dr zucconi is a senior management consultant and a member of the board of directors of pmtec inc a position that he has held since  dr zucconi has also served as president of implementation edge llc since  dr zucconi served as a management consultant to los alamos national laboratory from may  through september  dr zucconi received a bs in chemistry from villanova university a ms in chemistry from university of connecticut and a phd in chemistry from the state university of new york  member of the irpr committee financial tear sheet download library shareholder briefcase   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information press releases  galectin therapeutics inc contact us investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs newsroom home who we are what we do who we help overview press releases events  presentations corporate governance financial information stock information faqs email alert subscription press releases home » investor relations » press releases year all years          sort by date descending date ascending update press releases date title and summary view jul   galectin therapeutics to present at the singular research summer conference norcross ga july   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that harold shlevin phd the companys chief operating officer will be presenting on behalf of the company at the singular research summer solstice conference being hel html pdf jun   patent for reducing inflammatory response granted to galectin therapeutics norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that the company has received notice of allowance for a us patent for galactorhamnogalacturonate compositions for the treatment of a number of diseases associated with html pdf jun   galectin therapeutics announces important milestones towards completion of nash cx trial norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis skin disease and cancer announces the independent data safety monitoring board dsmb recently concluded that from a safety perspective the companys nashcx trial sh html pdf jun   autoimmune disease patent granted to galectin therapeutics norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that the company has been issued us patent  for composition of novel carbohydrate drug for treatment of human diseases the patents principal claims cover me html pdf may   galectin therapeutics reports  first quarter financial results and provides business update norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today reported financial results for the three months ended march   these results are included in the companys quarterly report on form q which has been filed with the us sec html pdf may   galectin therapeutics launches the liver line an online community and publication on liver health and liver disease norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced the launch of the liver line an online community and publication on liver health and liver disease  html pdf apr   galectin therapeutics receives notice of japanese decision to grant a composition of matter patent for grmd norcross ga april   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis skin diseases and cancer today announced that the company has received a decision to grant from the japanese patent office for its patent application for composition html pdf apr   galectin therapeutics and exalenz to present latebreaking abstract at the international liver congress™  norcross ga april   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins and exalenz bioscience taseexen a leader in developing and marketing noninvasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases today a html pdf mar   galectin therapeutics reports  financial results and provides business update norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today reported financial results for the year ended december   these results are included in the companys annual report on form k which has been filed with the us securitie html pdf mar   galectin therapeutics issues statement regarding galtw and galtu norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins announced today that trading will be halted in galtw and galtu at close of business on march   due to the expiration on march   of certain publicly traded warrants that we html pdf mar   galectin therapeutics reports fourth quarter and full year  financial results and provides business update norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins announced today that the company will release fourth quarter and full year  results before the market opens on tuesday march   a copy of the earnings release will be availabl html pdf mar   grmd demonstrates clinically significant effect in patients with severe and refractory atopic dermatitis eczema norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced preliminary results for severe and refractory atopic dermatitis from a small open label investigatorinitiated study with grmd that has enrolled  patients there we html pdf mar   galectin therapeutics to present at th annual roth conference norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that harold shlevin phd the companys chief operating officer will present at the th annual roth conference on wednesday march   at  am pacific time html pdf mar   galectins grmd demonstrates efficacy in patients with moderate to severe plaque psoriasis research done in partnership with san antonio military medical center showed an average  pasi reduction by end of week treatment period norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced results from an explorat html pdf feb   galectin therapeutics to present at bio ceo  investor conference norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that harold shlevin phd the companys chief operating officer will present at bio ceo  investor conference on monday february   at  pm eastern time the html pdf feb   combination immunotherapy with galectin inhibitor grmd enhances effects in preclinical models and early results of phase  clinical trials norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins and the providence cancer center today announced the presentation of preclinical and early clinical data from two investigatorinitiated phase  clinical trials of grmd used in combina html pdf feb   galectin therapeutics presentation now available for ondemand viewing company invites individual and institutional investors as well as advisors to logon to virtualinvestorconferencescom to view presentation norcross ga feb   cnw  galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins today announced that the february nd presenta html pdf feb   galectin therapeutics announces achievement of key milestones related to nashcx clinical trial norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced it has generated sufficient financing to cover currently planned expenditures through  and it remains on track to present top line data from its nashcx phase  clinica html pdf jan   galectin therapeutics to webcast live at virtualinvestorconferencescom on february  the company invites individual and institutional investors as well as advisors to attend interactive realtime virtual virtualinvestorconferencescom norcross ga jan   cnw  galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins today announced that peter g trabe html pdf dec   galectin therapeutics announces  million in new equity financings norcross ga dec   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced it has recently completed  a private placement of its common stock raising  in new funding  in a separate transaction the company also closed an additional sal html pdf dec   galectin therapeutics to webcast corporate update at annual meeting of stockholders norcross ga dec   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced that the company will present a corporate update via live webcast immediately following the business portion of its  annual meeting o html pdf nov   galectin therapeutics announces positive new psoriasis and atopic dermatitis clinical data seeking strategic partnerships for therapy of severe skin diseases norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins today announced its plans to identify a strategic partnership for its galectin inhibitor grmd for the treatment of serious skin diseases including html pdf nov   galectin therapeutics reports third quarter  financial results and provides business update norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the three and nine months ended september   these results are included in the company html pdf oct   galectin therapeutics to webcast corporate presentation at the microcap conference on october  in philadelphia norcross ga oct   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that peter g traber md the companys president chief executive officer and chief medical officer will present at the microc html pdf oct   galectin therapeutics to present clinical data on selective noninvasive tests for the development of novel therapies for nonalcoholic steatohepatitis norcross ga oct   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced it will present two posters that demonstrate the use of alternative noninvasive tests on the progression of cirrhosis and fi html pdf sep   galectin therapeutics announces topline data from exploratory phase a pilot trial nashfx with grmd in nash patients with advanced fibrosis larger phase b clinical trial in nash cirrhosis nashcx now completely enrolled closed private placement financing for  million conference call to be held today at  pm eastern time norcoss ga sept   globe newswire html pdf aug   galectin therapeutics to present at rodman  renshaw th annual global investment conference norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that peter g traber md the companys president chief executive officer and chief medical officer html pdf aug   galectin therapeutics announces results from week extension of phase a psoriasis clinical trial norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins announces interim results from an exploratory openlabel phase a clinical trial with grmd in patients with moderatetosevere plaque psoriasis i html pdf aug   galectin therapeutics reports second quarter  financial results and provides business update topline data from nashfx trial in nash patients with advanced fibrosis expected to be reported by the end of september australian patent allowance strengthens global intellectual property franchise norcross ga aug   globe newswire  galectin thera html pdf aug   galectin therapeutics announces completion of patient recruitment in its phase  trial with grmd in nash patients with cirrhosis norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces the completion of patient recruitment in its phase  clinical trial with grmd in patients with nonalcoholi html pdf jul   peter g traber md ceo and cmo of galectin therapeutics to speak on the medical applications of plantderived complex carbohydrates dr traber to speak on galectin therapeutics development of grmd for treatment of human disease norcross gabusiness wire galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today a html pdf jul   galectin therapeutics receives notice of australian patent to be granted for the use of grmd in liver kidney lung or heart fibrosis norcross gabusiness wire galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the company has received a notice of allowance from the australian government patent office for its patent ap html pdf jun   galectin therapeutics announces positive preclinical results on the role of galectin in mediating vascular remodeling in pulmonary arterial hypertension norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer reports that grmd its developmentstage galectin gal inhibitor has shown a positive effect on vascular remodeling in an anim html pdf may   galectin therapeutics announces positive interim results from phase a trial with grmd in moderatetosevere plaque psoriasis a significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional  weeks conference call to be held tomorrow at  am eastern time norcross ga may   globe newswire  galectin therapeu html pdf may   galectin therapeutics announces complete enrollment in its phase  trial with grmd in nash patients with advanced fibrosis norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces the completion of enrollment in its phase  clinical trial with grmd in patients with nonalcoholic steatohe html pdf may   galectin therapeutics reports first quarter  financial results and provides business update norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the three months ended march   these results are included in the companys form q which ha html pdf may   preclinical research on the role of galectin in pulmonary arterial hypertension to be presented at the american thoracic society  international conference norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer has received notification that its collaborative abstract with investigators at augusta university galectin mediates vascular remode html pdf apr   galectin therapeutics to present at needham  companys th annual healthcare conference norcross ga april   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that peter g traber md the companys president chief executive officer and chief medical officer wi html pdf mar   galectin therapeutics reports  financial results and provides business update norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the year ended december   these results are included in the companys annual report on form  html pdf mar   galectin therapeutics to hold business update conference call on march  norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that in conjunction with the filing of its annual report on form k it will hold a business update conference c html pdf mar   galectin therapeutics to present at the th annual roth conference norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces today peter g traber md the companys president chief executive officer and chief medical officer will present at the  html pdf feb   galectin therapeutics receives us patent allowance for grmd to treat pulmonary fibrosis norcross ga  feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces receipt of a notice of allowance from the united states patent and trademark office uspto for patent application number  html pdf jan   galectin therapeutics to present at upcoming conferences norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today peter g traber md the companys president chief executive officer and chief medical officer will present at the  html pdf jan   galectin therapeutics inc to present at noble financial capital markets th annual investor conference norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today peter traber md the companys president chief executive officer and chief medical officer will present html pdf jan   galectin therapeutics appoints dr marc rubin chairman of the board of directors norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces the election of marc rubin md as chairman of the board of directors dr rubin who has been serving as lead independent dir html pdf jan   galectin therapeutics posts  progress and possibilities to corporate website norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that the yearinreview post  progress and possibilities is now available on the companys website in the ceo p html pdf jan   galectin therapeutics announces dismissals of federal securities class action and shareholder derivative actions norcross ga jan   globe newswire  galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced that the united states district court for northern georgia has dismissed all claims against it and certain officers directors an html pdf jan   galectin therapeutics announces dismissals of federal securities class action and shareholder derivative actions norcross ga jan   globe newswire  galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced that the united states district court for northern georgia has dismissed all claims against it and certain officers directors and shareholder x  html pdf nov   galectin therapeutics announces pricing of  million registered direct offering norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of  shar html pdf nov   research underlying galectins development of grmd in cancer presented at the society for immunotherapy of cancer annual meeting norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that preclinical research from a study led by stefanie linch phd in the laboratory of tumor immunology expert william l redmond phd of the prov html pdf nov   galectin therapeutics reports third quarter  financial results and provides business update norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the three and nine months ended september   and provided a business update these results are included in the company html pdf oct   galectin therapeutics selected to present at cavendish global health impact forum norcross ga oct   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today it has been selected to present at the cavendish global health impact forum cohosted by the cleveland clinic and taking place october th to october html pdf oct   galectin therapeutics grmd to be studied in combination with keytrudar in patients with metastatic melanoma norcross ga oct   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that providence cancer center has filed an investigational new drug ind application with the us food and drug administration fda to study grmd html pdf oct   galectin therapeutics executive chairman to discuss silent epidemic and companys role in developing treatments for nash and other diseases at robins equity research roundup conference norcross ga oct   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that james czirr the companys executive chairman will present at the robins equity research roundup conference taking place october    html pdf oct   galectin therapeutics inc executive chairman jim czirr to be interviewed on the big biz show norcross ga  marketwired    galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that executive chairman jim czirr will be interviewed on the big biz show hosted by bob sully sullivan in this exclusive interview mr c html pdf sep   galectin therapeutics begins phase a psoriasis study with grmd norcross ga sept   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces the start of a patient pilot study with grmd in patients with moderatetosevere plaque psoriasis the genesis of this study is the app html pdf sep   galectin therapeutics to present at  ladenburg thalmann healthcare conference norcross ga sept   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that peter g traber md chief executive officer president and chief medical officer of galectin therapeutics will make a corporate presentatio html pdf sep   galectin therapeutics announces start of phase  clinical trial with grmd in nash with advanced fibrosis norcross ga sept   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces the commencement of its phase  clinical trial with grmd in patients with nonalcoholic steatohepatitis nash with advanced fibrosis the nashfx html pdf sep   galectin therapeutics to participate in three investment conferences in september norcross ga sept   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that executive management will be participating in three investment conferences in september as follows  peter g traber md chief executive offic html pdf aug   galectin therapeutics receives us patent notice of allowance for use of pectin compounds to reduce fibrosis in multiple diseases norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces receipt of a notice of allowance from the us patent and trademark office for patent application number  titled galactosepronged polysacc html pdf aug   galectin therapeutics provides phase  nash program update and reports second quarter  financial results norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the three and six months ended june   these results are included in the companys quarterly report on form q whi html pdf jul   galectin therapeutics inc appoints adam e allgood pharmd rph as executive director of clinical development norcross ga july   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of adam e allgood pharmd rph as executive director of clinical development effective immediately dr allgood is an exper html pdf jun   galectin therapeutics initiates enrollment for grmd phase  clinical trial in nash with cirrhosis norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the screening of the first five patients in its phase  clinical trial with grmd in nonalcoholic steatohepatitis nash with cirrhosis this st html pdf jun   galectin therapeutics names dr marc rubin lead independent director norcross ga june   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer reports that marc rubin md has been elected by the independent members of the board of directors as the lead independent director dr rubin has been a member  html pdf may   galectin therapeutics to present at ld micro invitational conference norcross ga may   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that james czirr executive chairman will present a corporate overview and update at the ld micro invitational conference on june   at  pm html pdf may   galectin therapeutics to webcast corporate update following annual meeting of stockholders norcross ga may   globe newswire  galectin therapeutics nasdaqgalt will webcast a corporate update at  am et on thursday may   immediately following the business portion of the companys annual meeting of stockholders additionally peter traber md president chief executive officer and chief medical officer will html pdf may   galectin therapeutics reports no drugdrug interaction between grmd and midazolam norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer reports that in an openlabel phase  study with  mgkg dose of grmd and  mgkg dose of midazolam there was no drugdrug interaction and no serious adverse  html pdf may   galectin therapeutics reports first quarter  financial results provides business update including phase  nash program norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the three months ended march   these results are included in the companys quarterly report on form q which has b html pdf mar   galectin therapeutics presented research with grmd at the american association for the study of liver diseases industry colloquium norcross ga march   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that peter g traber md president chief executive officer and chief medical officer delivered an invited presentation of the companys research with  html pdf mar   galectin therapeutics reports  financial results provides business update norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported financial results for the year ended december   these results are included in the companys annual report on form k which has been fi html pdf mar   galectin therapeutics engages ppd to conduct grmd phase  trial in nash submits special protocol assessment to fda norcross ga march   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces it has engaged the contract research organization pharmaceutical product development llc ppd to conduct the phase  trial with grmd for the treatmen html pdf mar   galectin therapeutics to present at the th annual roth conference norcross ga march   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that harold shlevin phd chief operating officer will present a corporate overview and update at the th annual roth conference on march    html pdf feb   galectin therapeutics announces details of the design of its phase  program with grmd program to include one trial to confirm the safety and therapeutic effect on fibrosis in nash patients with cirrhosis and a smaller trial to confirm the safety and therapeutic effect on nash patients with advanced fibrosis both studies to begin in the second quarter of  company to submit a special protocol assessment to the fda by the end of t html pdf jan   final phase  trial results demonstrate galectin therapeutics grmd is safe with potential for therapeutic effect on fibrosis in nash patients with advanced fibrosis norcross ga jan   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announces that final results from its phase  trial show that grmd had an effect on a serum biomarker as assessed by fibrotest® and liver stiffness as asse html pdf dec   galectin therapeutics to present at th annual ld micro main event conference norcross ga dec   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that james c czirr executive chairman of the companys board of directors will present at the ld micro main event microcap growth conference html pdf nov   galectin therapeutics reports third quarter  financial results and provides update on companys development program norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the third quarter and nine months ended september   these results are included in the companys quarterly report html pdf nov   galectin therapeutics phase  data presented at aasld annual meeting advances grmd into phase  clinical development norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer presented data today from the companys phase  clinical trial of grmd in nash fatty liver disease patients with advanced fibrosis at the liver meeting in b html pdf oct   galectin therapeutics abstract accepted as oral presentation at the liver meetingr annual meeting of the american association for the study of liver diseases norcross ga oct   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the companys abstract titled early phase  clinical trial results of grmd a galectin inhibitor in patients having nonalcoholic ste html pdf sep   galectin therapeutics elects gilbert s omenn md phd a leading cancer researcher to its board of directors norcross ga sept   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the election of gilbert s omenn md phd to its board of directors effective immediately dr omenn a leading cancer researcher is a pr html pdf sep   galectin therapeutics announces issuance of us patent for grmd in diabetic nephropathy norcross ga sept   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the us patent and trademark office has issued a patent for the companys application titled galactosepronged carbohydrate compounds for html pdf sep   galectin therapeutics to present at aegis capital corporation  healthcare and technology conference norcross ga sept   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the company will present at the aegis capital corporation  healthcare and technology conference in las vegas nev on friday september  html pdf aug   galectin therapeutics reports second quarter  financial results norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the three and six months ended june   these results are included in the companys quarterly report on form q  html pdf aug   galectin therapeutics receives us patent for grmd composition of matter norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of allowance from the us patent and trademark office for patent application number  titled composition  html pdf aug   galectin therapeutics responds to class action lawsuit norcross ga aug   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer issued the following statement today we have become aware that a putative class action lawsuit has been filed against galectin therapeutics and certain officers o html pdf jul   galectin therapeutics issues statement on grmd development program norcross ga july   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced yesterday results of cohort  of its phase  clinical trial in patients with nash with advanced fibrosis while the results of the clinical trial were posit html pdf jul   galectin therapeutics to host webcast to discuss findings from cohort  of phase  clinical trial of grmd in fatty liver disease with advanced fibrosis norcross ga july   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced the company will hold a webcast on tuesday july   at  am eastern daylight time to discuss the findings from cohort  of a phase  clinical tri html pdf jul   galectin therapeutics announces first patient dosed in cohort  of phase b clinical trial of grmd in combination with ipilimumab in metastatic melanoma norcross ga july   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the first patient has been dosed in cohort  of the companys phase b clinical trial evaluating grmd in combination with ipilimumab ye html pdf jul   galectin therapeutics added to russell  index norcross ga july   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced that it has been added to the russell ® index and russell ® index when russell investments reconstituted its comprehensive set of us html pdf jun   galectin therapeutics announces that oral treatment with galectin inhibitor grmd is efficacious in preclinical model of fatty liver disease with fibrosis norcross ga june   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that a preclinical study in a mouse model of nash nonalcoholic steatohepatitis or fatty liver disease demonstrated that oral administration of the html pdf may   galectin therapeutics to present at jefferies  global healthcare conference norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the company will present at the jefferies  global healthcare conference to be held june   in new york ny dr harold h shlevi html pdf may   galectin therapeutics receives us patent for grmd in diabetic nephropathy a progressive kidney disease norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of allowance from the us patent and trademark office for patent application number  titled galactosepr html pdf may   galectin therapeutics reports first quarter  financial results norcross ga may   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the quarter ended march   these results are included in the companys quarterly report on form q which has be html pdf may   galectin therapeutics to hold conference call to provide corporate update following companys annual meeting of shareholders atlanta may   globe newswire  galectin therapeutics nasdaqgalt will host a conference call at  am eastern time on wednesday may   to provide a corporate update following the companys annual meeting of shareholders additionally peter traber md president ceo and cmo of galectin therapeutics will update the investme html pdf apr   galectin therapeutics completes enrollment of second cohort of phase  trial of grmd for nash fatty liver disease with advanced fibrosis norcross ga april   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that all eight  patients have received their first infusion in cohort  of its phase  clinical trial of grmd in patients with nash with advan html pdf apr   galectin therapeutics announces first patient dosed in second cohort of phase  trial of grmd for nash with advanced fibrosis norcross ga april   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that the first patient in cohort  of its phase  clinical trial of grmd in patients with nash with advanced fibrosis has been successfully dosed html pdf mar   first cohort results in galectin therapeutics phase  trial reveal biomarker evidence of therapeutic effect on fibrosis and inflammation in nash with advanced fibrosis grmd was safe and well tolerated in patients galectin therapeutics to host webcast april   am edt to discuss first cohort findingssecond cohort of phase  trial to begin enrollment in april norcross ga march   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galect html pdf mar   galectin therapeutics to announce results from first cohort of phase  clinical trial in fatty liver disease norcross ga march   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced that on monday march   the company will report results from the first cohort of its phase  clinical trial examining grmd in fatty liver disea html pdf mar   galectin therapeutics reports  financial results norcross ga march   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the year ended december   these results are included in the companys annual report on form k which has bee html pdf feb   galectin therapeutics secures us patent for its proprietary galectin inhibitor grmd in fatty liver disease norcross ga feb   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the us patent and trademark office issued patent number  to the company for its application titled galactorhamnogalacturonate compos html pdf feb   galectin therapeutics presents at jmp securities nonalcoholic steatohepatitis nash workshop norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the company will present at the nonalcoholic steatohepatitis nash workshop hosted by jmp securities on thursday february   in new  html pdf feb   galectin therapeutics ceo serves on cancer immunotherapy panel at bio ceo  investor conference norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that peter g traber md chief executive officer president and chief medical officer of galectin therapeutics served on a panel titled keep html pdf feb   galectin therapeutics to present at th annual bio ceo  investor conference norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the company will present at the th annual bio ceo  investor conference to be held february   at the waldorf astoria hotel in n html pdf feb   galectin therapeutics and providence portland medical center receive ok from fda to proceed with phase b clinical trial in metastatic melanoma norcross ga feb   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the us food and drug administration fda has agreed that a phase b clinical trial of the galectin inhibitor grmd in combination with  html pdf jan   galectin therapeutics inc and sbh sciences inc announce the formation of galectin sciences llc a collaborative venture to research and develop galectin inhibitors for oral administration norcross ga and natick mass jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer and sbh sciences inc a world leader in cellbased assays to measure biological activity and developer of cytokines growth factors biologic html pdf jan   galectin therapeutics executive chairman james czirr to present at redchip emerging growth showcase norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that its executive chairman james czirr will present during the redchip emerging growth showcase on thursday january   at  am east html pdf jan   preclinical study demonstrates effect of galectin inhibitor on serum biomarker in fatty liver disease with fibrosis norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that data from a preclinical study show its leading galectininhibiting drug grmd demonstrates an effect on a blood biomarker in an animal mo html pdf jan   galectin therapeutics supports investigational new drug ind application for its galectin inhibitor grmd in metastatic melanoma norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that providence portland medical center filed an investigational new drug ind application with the us food and drug administration fda on d html pdf jan   galectin therapeutics announces completion of enrollment in first cohort of phase  trial of grmd in fatty liver disease with advanced fibrosis norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that patient enrollment in the first cohort of a phase  trial of grmd is now complete the firstinman study which has successfully enroll html pdf jan   galectin therapeutics announces update on financing activities and cash of  million norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it had sold from october   through january   a total of  shares of common stock at an average price per share of  html pdf jan   galectin therapeutics reports on key  scientific development and regulatory milestones highlights corporate and financial activity norcross ga jan   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today released a report on the companys key scientific development and regulatory milestones and corporate activity that contributed to the companys progress i html pdf jan   galectin therapeutics receives us patent for combination treatment for liver fibrosis norcross ga jan   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of allowance from the us patent and trademark office for patent application number  titled galactosepronged html pdf dec   published preclinical study demonstrates therapeutic effect of galectin inhibitors in fatty liver disease with fibrosis norcross ga dec   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that new preclinical data show its leading galectininhibiting drugs — grmd and gmct — demonstrate positive therapeutic effec html pdf nov   galectin therapeutics reports update on enrollment of first cohort of phase  clinical trial and third quarter  financial results norcross ga nov   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported that five of the eight patients have been enrolled and infused in cohort  of its blinded phase  clinical trial of grmd for patients with non html pdf oct   galectin therapeutics announces early warrant exercise by x fund provides update on cash position norcross ga oct   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that x fund has exercised  common stock purchase warrants of galectin therapeutics at  per share for total cash proceeds of  th html pdf oct   galectin therapeutics preclinical data published in plos one show its galectin inhibitors reverse cirrhosis and significantly reduce fibrosis and portal hypertension norcross ga oct   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that new preclinical data show its galectin inhibitors grmd and gmct have significant therapeutic effects on fibrosis regression and cirr html pdf sep   galectin therapeutics leadership to present at three upcoming conferences norcross ga sept   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that company leadership will present at three upcoming conferences these presentations are part of a long standing and ongoing effort to communic html pdf sep   galectin therapeutics receives us patent for potential groundbreaking treatment for fatty liver disease norcross ga sept   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of issuance from the us patent and trademark office for patent application number  titled galactorhamnoga html pdf aug   galectin therapeutics announces update on warrant exercises norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced all of the  common stock purchase warrants scheduled to expire on august   have been exercised for total cash proceeds of  millio html pdf aug   galectin therapeutics announces  million private placement of restricted stock norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced completion of a  million private placement of  shares of unregistered common stock to a single investor the common stock was priced at  html pdf aug   galectin therapeutics reports second quarter  financial results norcross ga aug   globe newswire  galectin therapeutics inc nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the second quarter and first six months ended june   these results are included in the companys q html pdf aug   galectin therapeutics receives fda fast track designation for grmd for fatty liver disease with advanced fibrosis norcross ga aug   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the us food and drug administration fda has granted grmdo galactoarabinorhamnogalacturonate fast track designation for nonalcoholic st html pdf aug   reduction in lung fibrosis with the antigalectin drug grmd revealed in preclinical data norcross ga aug   globe newswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced new preclinical data on the efficacy of antigalectin therapy for lung fibrosis using a model that simulates the human disease idiopathic pulmonary fib html pdf jul   galectin therapeutics announces first patient dosed in phase  trial of grmd a potential firstinclass treatment for fatty liver disease with advanced fibrosis norcross ga july   prnewswireusnewswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that the first patient has been successfully dosed in a phase  clinical trial of grmd the firstinman study will evaluate th html pdf jul   galectin therapeutics submits fast track application to fda for grmd in treatment of fatty liver disease with advanced fibrosis norcross ga july   prnewswire  galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that it has submitted a fast track application to the fda to help expedite its clinical development program of grmd in the treatment of nonalcoholic  html pdf jun   galectin therapeutics names industryveteran jack w callicutt chief financial officer norcross ga june   prnewswire  galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of jack w callicutt to the position of chief financial officer effective july  mr callicutt will lead t html pdf jun   tumor immunotherapy efficacy increased in both breast and prostate cancer preclinical models with addition of galectin inhibitor norcross ga june   prnewswireusnewswire  galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that preclinical studies have shown that combining the galectin inhibitor grmd with monoclonal antibodies that function as imm html pdf may   galectin therapeutics to hold conference call to provide update following companys annual meeting of shareholders  new phone number for audio portion of presentation atlanta may   prnewswire  galectin therapeutics nasdaq galt will host a conference call at  am eastern time on thursday may   to provide an update following the companys annual meeting of shareholders due to technological difficulties a different phone number than previously circulated will be used for accessing th html pdf may   galectin therapeutics to hold conference call to provide update following companys annual meeting of shareholders atlanta may   prnewswire  galectin therapeutics nasdaq galt will host a conference call at  am eastern time on thursday may   to provide an update following the companys annual meeting of shareholders additionally peter traber md president ceo and cmo of galectin therapeutics will update the investme html pdf may   galectin therapeutics reports first quarter  financial results norcross ga may   prnewswire  galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the first quarter ended march   these results are included in the companys quarterly report on form q which html pdf apr   galectin inhibitors reverse liver cirrhosis in preclinical studies norcross ga april   prnewswire  galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today released data that was presented on april   at the international liver congress in amsterdam the netherlands the data were generated by the l html pdf apr   galectin therapeutics to present new data on the treatment of liver fibrosis and cirrhosis norcross ga april   prnewswire  galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that its abstract was accepted by the european association for the study of the liver for presentation on april   at the internationa html pdf apr   clinical trial sites for first human clinical trial for treatment of fatty liver disease with advanced fibrosis announced by galectin therapeutics norcross ga april   prnewswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced details today on its firstinman phase  clinical trial that will support a proposed indication of grmd for treatment of nonalcoholic steatohe html pdf apr   galectin therapeutics turning atlanta into americas next silicon valley norcross ga april   prnewswire  gilbert amelio former ceo of apple and rod martin former counsel to paypal both on the board of directors of galectin therapeutics nasdaq galt authored an opinion piece in todays atlanta journal constitution discussing the future of atlanta as the emerging silicon valley for changing  html pdf mar   galectin therapeutics reports full year and fourth quarter  financial results norcross ga march   prnewswire galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the full year and fourth quarter ended december   these results are included in the companys quarterly  html pdf mar   galectin therapeutics inc receives ok from fda to proceed with first human clinical trial for treatment of fatty liver disease with advanced fibrosis norcross ga march   prnewswire  galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that following review of its investigational new drug ind application the us food and drug administration fda notified the company that i html pdf feb   galectin therapeutics announces discovery program for new antigalectin drugs in collaboration with the university of georgia norcross gabusiness wirefeb   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today the establishment of a collaborative drug discovery program with dr geertjan boons’ laboratory located in the complex carbohydrate research c html pdf feb   galectin therapeutics executive chairman james czirr to appear on the redchip money report on fox business news norcross gabusiness wirefeb   james czirr executive chairman of galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer will be a guest on “the redchip money report”™ television program featuring emerging growth companies on fox busi html pdf jan   galectin therapeutics inc announces submission of an investigational new drug ind application for the treatment of fatty liver disease norcross gabusiness wirejan   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer announced today that it submitted an investigational new drug ind application to the us food and drug administration fda on january   the ind application html pdf jan   galectin therapeutics inc announces publication of galectin symposium proceedings by the american chemical society norcross gabusiness wirejan   galectin therapeutics nasdaqgalt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the american chemical society acs as part of its acs symposium series has published online the proceedings from the galectinfocused symposiu html pdf jan   new potential therapy for diabetic kidney disease galectin therapeutics announces antigalectin drug is effective in preclinical studies norcross gabusiness wirejan   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced new preclinical data on the efficacy of antigalectin therapy on diabetic kidney disease treatment of diabetic mice with grmd was found to rever html pdf jan   galectin therapeutics appoints industry veteran rex horton as executive director of regulatory affairs and quality assurance norcross gabusiness wirejan   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of rex horton as executive director of regulatory affairs and quality assurance mr horton is an experienced industry professio html pdf nov   galectin therapeutics receives us patent for second drug class to treat chronic liver disease with fibrosis scarring and cirrhosis norcross gabusiness wirenov   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of allowance from the us patent and trademark office for a divisional patent of patent number  “galact html pdf nov   galectin therapeutics presents new data on the treatment of fatty liver disease and fibrosis at aasld  norcross gabusiness wirenov   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today presented new preclinical data on the mechanism of action of grmd at the american association for the study of liver disease aasld annual meeting in bosto galectin poster presentation from the aasld annual meeting html pdf nov   galectin therapeutics reports third quarter  financial results norcross gabusiness wirenov   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the third quarter and first nine months ended september   these results are included in the companys quarterl html pdf oct   galectin therapeutics to present new data on the treatment of fatty liver disease and fibrosis at aasld  norcross gabusiness wireoct   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it will present at the american association for the study of liver disease aasld annual meeting on november   in boston ma html pdf sep   galectin therapeutics hosted international conference on galectins and disease newton massbusiness wiresep   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the proceedings of an international galectin meeting hosted by galectin therapeutics and held at the harvard club in boston ma on september  html pdf aug   galectin therapeutics announces relocation of corporate headquarters to atlanta ga newton massbusiness wireaug   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that as of october   its corporate offices will be moved to atlanta georgia while maintaining a laboratorybased effort in the boston area  html pdf aug   galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer newton massbusiness wireaug   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of dr harold h shlevin as chief operating officer dr shlevin succeeds as of october   maureen foley who helped found html pdf aug   galectin therapeutics to present at the redchip smallcap equities virtual conference newton massbusiness wireaug   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it will present at the redchip smallcap equities virtual conferencethe company’s presentation will be webcast live at h html pdf aug   galectin therapeutics reports second quarter  financial results newton massbusiness wireaug   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the second quarter and first six months ended june   these results are included in the companys quarterly re html pdf aug   galectin therapeutics planning clinical trials for early  to treat fatty liver disease with advanced fibrosis after recent fda meeting newton massbusiness wireaug   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced its clinical development program for the treatment of nonalcoholic steatohepatitis nash or fatty liver disease with advanced fibrosis galectin t html pdf jul   galectin therapeutics receives us patent for potential groundbreaking treatment for chronic liver disease with fibrosis scarring and cirrhosis newton massbusiness wirejul   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has received a notice of issuance from the us patent and trademark office for patent number  “galactoseprolonged polysaccha html pdf jul   galectin therapeutics announces addition to russell microcap index newton massbusiness wirejul   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it has been added to the russell microcap index effective at the close of equity markets on june  annual reconstitution of r html pdf jun   galectin therapeutics to host symposium on galectin science and therapeutic applications september   newton massbusiness wirejun   galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that the company will host the galectin science and therapeutic applications symposium september   in boston massachusetts the symposium html pdf may   galectin therapeutics to hold conference call to provide update following companys annual meeting of shareholders newton massbusiness wiremay   galectin therapeutics nasdaq galt will host a conference call at  am eastern time on thursday may   to provide an update following the company’s annual meeting of shareholders additionally peter traber md president ceo and cmo of galectin therapeutics will update the in html pdf may   galectin therapeutics announces initiation of phase  trial of novel combination therapy for advanced metastatic melanoma newton massbusiness wiremay   galectin therapeutics nasdaq galt “the company” the leader in developing carbohydratebased therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer today announced that the first patient has been dosed in a phase  trial evaluating the safe html pdf may   galectin therapeutics reports first quarter  financial results newton massbusiness wiremay   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for first quarter ended march   these results are included in the companys quarterly report on form q which html pdf may   galectin therapeutics announces longterm engagement of dr scott friedman to advise on liver fibrosis programs newton massbusiness wiremay   galectin therapeutics inc nasdaq galt “the company” the leader in developing carbohydratebased therapeutic compounds to inhibit galectin proteins for therapy of liver fibrosis and cancer today announced entering into a fiveyear consulting agreement with worldrenowned expert in l html pdf apr   galectin therapeutics to present promising new therapeutic approach for fatty liver disease at digestive disease week  newton mass apr   business wire galectin therapeutics nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced that it will present at digestive disease week may   in san diego ca peter g traber md president ceo and cmo of galectin will present  html pdf mar   galectin therapeutics reports full year and fourth quarter  financial results newton massbusiness wiremar   galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the full year and fourth quarter ended december   these results are included in the companys annual  html pdf mar   galectin therapeutics inc announces closing of public offering of  units newton massbusiness wiremar   galectin therapeutics inc nasdaq galt galtu galtw today announced it has closed its underwritten public offering of  units including  units that were offered and sold by galectin pursuant to the exercise infull of the underwriter’s overallotment option at a price to th html pdf mar   galectin therapeutics inc announces exercise of overallotment option galectin therapeutics inc announces exercise of overallotment optionnewton massbusiness wiremar   galectin therapeutics inc nasdaq galt nasdaq galtu announced the full exercise of the overallotment option granted to the underwriter to purchase  additional units at a public offering price of  per  html pdf mar   galectin therapeutics inc announces pricing of public offering of  units listing on nasdaq and effectiveness of reverse stock split newton massbusiness wiremar   galectin therapeutics inc nasdaq galt today announced the pricing of an underwritten public offering of  units at a price to the public of  per unit with each unit consisting of two common voting shares par value  per share the “common stock” and one warrant t html pdf mar   galectin therapeutics inc appoints thomas a mcgauley as acting chief financial officer and extends term of employment of maureen e foley as chief operating officer newton massbusiness wiremar   galectin therapeutics inc otc galt the “company” announced today that it has appointed thomas a mcgauley as the acting chief financial officer of the company effective march   mr mcgauley will serve as acting chief financial officer until the earlier of september   a html pdf feb   galectin therapeutics to present corporate update at bio ceo  investor conference newton massbusiness wirefeb   galectin therapeutics inc otc galt the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that dr peter g traber chief executive officer president and chief medical officer is scheduled to present a corporate update at the bio ceo  html pdf dec   galectin therapeutics provides corporate update newton massbusiness wiredec   galectin therapeutics inc otc galt the leader in developing carbohydratebased therapeutic compounds to inhibit galectin proteins today issued the following corporate update to its shareholdersdear galectin therapeutics stockholderas  draws to a close we are very p html pdf dec   galectin therapeutics presents preclinical data on the treatment of fatty liver disease and fibrosis at easl newton massbusiness wiredec   galectin therapeutics inc otc galt the leader in developing carbohydratebased therapeutic compounds to inhibit galectin proteins today announced that it presented a poster at the european association for the study of the liver easl special conference on liver transplantation in lisbon portu html pdf dec   novel cancer treatment combination receives approval to begin firstinhuman testing for patients with advanced metastatic melanoma newton mass  new york  brussels dec   business wire  galectin therapeutics the cancer centre at the cliniques universitaires saintluc and the ludwig institute for cancer research licr announced today that they will initiate a phase  safety and efficacy trial testing a novel treatment combination in patients with advanced meta html pdf nov   galectin therapeutics reports third quarter and nine months  financial results newton mass nov   business wire  galectin therapeutics inc otc galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the third quarter and first nine months ended september   these results are included in the companys qua html pdf nov   galectin therapeutics announces formation of liver fibrosis clinical trials advisory board newton mass nov   business wire  galectin therapeuticsinc otc galt the company the leader in developing carbohydratebased therapeutic compounds to inhibit galectin receptors today announced the formation of its liver fibrosis clinical trials advisory board comprised of key opinion leaders from emory hospital and school of m html pdf oct   galectin therapeutics to announce new data on the treatment of fatty liver disease and fibrosis newton mass oct   business wire  galectin therapeuticsinc otc galt the leader in developing carbohydratebased therapeutic compounds to inhibit galectin proteins today announced that its abstract was accepted by the european association for the study of the liver easl for presentation at its special conference on liver transpla html pdf oct   galectin therapeutics elects dr marc rubin to its board of directors newton mass oct   business wire  galectin therapeutics otc galt the leading developer of galectin inhibitor therapeutic compounds to treat fibrosis and cancer today announced the election of dr marc rubin to its board of directors effective today titan pharmaceuticals inc is a biopharmaceutical company focused on the develop html pdf oct   galectin therapeutics board member john mauldin plans to purchase stock under b plan company featured in his enewsletter thoughts from the frontline newton mass oct   business wire  galectin therapeuticsinc otc galt today announced that john mauldin a member of its board of directors plans to purchase company stock on a periodic basis by entering into a b plan and on october st featured the company in his enewsletter thoughts from the frontline a highly acclaime html pdf sep   galectin therapeutics posts new corporate presentation video to its website newton mass sep   business wire  galectin therapeuticsinc otc galt today announced that it posted a new corporate presentation video to its website httpwwwgalectintherapeuticscom that highlights the companys leadership position in developing galectininhibiting therapeutics to treat fibrosis and cancer the video is narra html pdf sep   galectin therapeutics to present corporate update at the rodman  renshaw healthcareconference newton mass sep   business wire  galectin therapeuticsinc otc galt today announced that peter g traber md chief executive officer will present a corporate update at the rodman  renshaw healthcare conference on tuesday september th at the waldorfastoria hotel in new york city dr trabers presentation is scheduled to be html pdf aug   galectin therapeutics reports financial results for second quarter  newton mass aug   business wire  galectin therapeutics inc otc galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the second quarter and first six months ended june   these results are included in the companys quarterl html pdf aug   x fund issues statement regarding investment in galectin therapeutics niceville fla aug   business wire  rod d martin managing member of x capital management llc the general partner of x fund lp x fund the largest shareholder of galectin therapeutics inc otc galt today issued the following statementon june   x fund materially increased its ownership position  html pdf jul   galectin therapeutics announces research collaboration with dr jose jalife of the university of michigan medical school to explore role of galectins in cardiovascular disease newton mass jul   business wire  galectin therapeuticsinc otc galt today announced that it has entered into a research collaboration with dr jose jalife of the university of michigan medical school to better understand the relationship of galectin to cardiac fibrosis in chronic cardiac arrhythmias galectin is known to be inc html pdf jun   adding and replacing galectin therapeutics announces new stock trading symbol galt newton mass jun   business wire  adding searchability for the ticker otc prwpthe corrected release readsgalectin therapeutics announces new stock trading symbol galtgalectin therapeuticsinc otc galt today announced that the financial industry regulatory authority finra approved the chan html pdf jun   galectin therapeutics expands european patent coverage newton mass jun   business wire  galectin therapeuticsinc otc prwp today announced that the european patent office has granted the company a new patent no  coadministration of a polysaccharide with a chemotherapy for the treatment of cancer the patent protects among other things methods for reducing the toxicity html pdf jun   galectin therapeutics to present corporate update at niba conference newton mass jun   business wire  galectin therapeuticsinc otc prwp today announced that peter g traber md chief executive officer will present a corporate update at the national investment banking association niba conference on june th and th to be held at the st regis atlanta hotel in atlanta georgiagale html pdf jun   galectin therapeutics announces the appointment of kevin freeman and john mauldin to the board of directors newton mass jun   business wire  galectin therapeuticsinc otc prwp today announced the appointment of two new members to the board of directors kevin d freeman cfa and john mauldin the two new directors will provide significant business acumen to galectin therapeutics with the additions galectin therapeutics board of direc html pdf may   stockholders approve all proposals at galectin therapeutics annual stockholders meeting newton mass may   business wire galectin therapeuticsinc otc prwp today announced that its stockholders have approved all five proposals at its annual stockholders meeting held on may   included in those proposals stockholders elected retired judge paul pressler to fill a vacancy on the board and gave the boar html pdf may   propharmaceuticals changes company name to galectin therapeutics newton ma – may   – propharmaceuticals inc otc prwp today announced that it has changed its name to galectin therapeutics inc to more accurately reflect the company’s core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and  html pdf may   propharmaceuticals to hold conference call to provide update following companys annual meeting of stockholders newton mass may   – propharmaceuticals inc otc prwp will host a conference call at  am eastern time on thursday may   to provide an update following the company’s annual meeting of stockholders the conference call and presentation will be webcast live over the internet and can be a html pdf may   propharmaceuticals reports first quarter  financial results newton massbusiness wirepropharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today reported its financial results for the first quarter ended march   these results are included in the company’s quarterly report on form q which has been file html pdf may   propharmaceuticals presentation at noble financial capital markets seventh annual equity conference to be webcast live newton mass may    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin proteins to treat cancer and fibrosis today announced that james c czirr executive chairman is scheduled to present a corporate update at noble financial capital markets’ seventh annual equities conference on tu html pdf may   propharmaceuticals selects safc® to rampup the manufacture of davanat® for anticipated use in clinical trials  sales in colombia newton mass may    propharmaceuticals inc otc prwp the leader in galectin therapeutics today announced it signed a multiyear agreement with safc® the custom manufacturing business unit of sigmaaldrichtm nasdaq sial to rampup the manufacture of the bulk drug substance or active pharmaceutical ingredient api for its  html pdf apr   propharmaceuticals expands patent coverage to japan newton massbusiness wirepropharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin proteins to treat cancer and fibrosis today announced that the japan patent office has accepted a new patent no  “coadministration of a polysaccharide with a chemotherapy for the treatment of cancer html pdf apr   the ludwig institute and propharmaceuticals discover that davanat® enhances the ability of antitumor t lymphocytes to kill tumor cells newton mass april    propharmaceuticals inc otcprwp today announced that the brussels branch of the ludwig institute for cancer research demonstrated the ability of gmct davanat® to enhance the ability of tumorspecific tlymphocytes to kill tumor cellsdr pierre van der bruggen’s team at the ludwig  html pdf mar   propharmaceuticals expands patent portfolio with new patents in the us and australia newton mass march    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that the company has been granted two new patents “coadministration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer” i html pdf mar   propharmaceuticals reports full year and fourth quarter  financial results newton massbusiness wirepropharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today reported its financial results for full year and fourth quarter ended december   these results are included in the company’s annual report on form k which h html pdf mar   propharmaceuticals names peter g traber md former glaxosmithkline chief medical officer  president emeritus of baylor college of medicine president  chief executive officer newton mass march    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that its board of directors named peter g traber md president and chief executive officer effective march   dr traber was named interim chief medi html pdf feb   propharmaceuticals to present corporate update at bio ceo  investor conference newton mass february    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that company executives are scheduled to present a corporate update at the bio ceo  investor conference on tuesday february   at am et at the waldorf html pdf jan   propharmaceuticals receives positive fda feedback on davanat® phase iii clinical trial design to treat patients with colorectal cancer newton mass january   propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that on december   company representatives met with officials from the us food  drug administration fda to present its phase lll clinical development  html pdf jan   propharmaceuticals closes  million offering newton mass january    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that it has closed a private placement for gross cash proceeds of approximately  for shares of its series c super dividend convertible preferred stock  html pdf jan   propharmaceuticals to present corporate update at san francisco biotech conference newton mass january    propharmaceuticals inc otc prwp a leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that company executives are scheduled to present a corporate update at the biotech showcase conference on wednesday january   at am pt at the parc   html pdf dec   propharmaceuticals  mount sinai school of medicine announce new liver fibrosis research collaboration newton mass december    propharmaceuticals inc otc prwp the leading developer of galectin therapeutics to treat cancer and fibrosis today announced it has entered into a new research collaboration with mount sinai school of medicine to evaluate in preclinical models the antifibrotic effects of several of the company’s  html pdf dec   propharmaceuticals expands patent coverage to australia newton mass december    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that the australian patent  trademark office has accepted a new patent no  “coadministration of a polysaccharide with a chemotherapy for th html pdf nov   propharmaceuticals reports third quarter  newton mass november    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today reported its financial results for the third quarter and the nine months ended september   these results are included in the company’s quarterly report on form q html pdf nov   propharmaceuticals to receive  in federal grants for its galectintargeting cancer and liver fibrosis compounds newton mass november    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced it has been notified that it has been awarded approximately  total in two federal grants under the qualifying therapeutic discovery project “qtdp” p html pdf oct   propharmaceuticals ships first commercial order for davanat® newton mass october    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced it has shipped its first commercial order of davanat® to procaps sa a large international pharmaceutical company based in barranquilla colombia the html pdf sep   propharmaceuticals collaborates with numoda to manage phase lll clinical trial to increase speedtomarket for davanat® newton mass september    propharmaceuticals inc otc prwp propharmaceuticals inc the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that it has engaged the numoda corporation a leading information process and logistics management company to overse html pdf sep   propharmaceuticals presentation at rodman and renshaws annual global investment conference to be webcast live newton mass september    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that company executives are scheduled to present a corporate update at rodman and renshaw’s annual global investment conference on monday september   at  html pdf aug   propharmaceuticals executives to present corporate update at three investor conferences in september newton mass august    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that theodore zucconi phd chief executive officer james czirr executive chairman of the board of directors and peter traber md chief medical officer propharma html pdf aug   propharmaceuticals reports second quarter  and six months financial results newton mass august    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today reported its financial results for the second quarter and the first six months ended june   these results are included in the company’s quarterly report on form q html pdf jun   propharmaceuticals receives first commercial order for davanat® newton mass june    propharmaceuticals inc otcbb prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced it has received its first purchase order for davanat® from procaps sa a large international pharmaceutical company based in barranquilla colombia pro html pdf jun   former glaxo smith kline chief medical officer peter g traber md named chief medical officer of propharmaceuticals newton mass june    propharmaceuticals inc otcbb prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today named dr peter g traber acting chief medical officer to lead the fda phase lll colorectal cancer trial for davanat® as well as the overall fda approval process  html pdf may   propharmaceuticals prepares phase iii davanat® trial for second half  newton mass may    propharmaceuticals inc otcbb prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced plans to submit a phase iii trial design for davanat® to the us food and drug administration fda during the second half of  the company has added th html pdf may   propharmaceuticals reports first quarter  financial results newton mass may    propharmaceuticals inc otcbb prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today reported its financial results for the first quarter ended march   these results are included in the company’s quarterly report on form q which has been filed wit html pdf may   propharmaceuticals closes final  tranche from x fund to complete  million raise newton ma may   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed the  final tranche to complete a  million private placement with x fund lp which is purchasing unregistered series b convertible preferred stock and warrantsat the x fund closing which occ html pdf may   propharmaceuticals closes  tranche from x fund newton ma may    propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date from t html pdf apr   colombian president uribe welcomes propharmaceuticals and introduction of davanat® to colombia newton mass april    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that its management met with colombia’s president alvaro uribe and the country’s viceminister of health carlos cuervo valencia at the presidential palace in b html pdf mar   propharmaceuticals reports full year and fourth quarter  financial results newton mass march    propharmaceuticals inc otc prwpob a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today reported its financial results for full year and fourth quarter ended december   these results are included in the company’s annual report on form k which has  html pdf mar   propharmaceuticals closes  tranche newton ma march    propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date fro html pdf feb   propharmaceuticals receives final tranche of funding from federal grant raises cash position to  million newton mass february    propharmaceuticals inc otc prwp the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced it has received the final tranche of  of the  in federal grant funding under the qualifying therapeutic discovery project “qtdp”  html pdf feb   propharmaceuticals closes  tranche newton ma february    propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date f html pdf dec   propharmaceuticals announces significant advance in defining davanat®s mechanism of action based on experiments done at the university of minnesota and the ludwig institute in brussels belgium newton ma – december   – propharmaceuticals inc otc prwp a developer of galectintargeting carbohydrate therapeutic compounds to treat cancer and fibrosis today announced it has made significant advances in determining the mechanism of action for its lead drug davanat® recent studies conducted by dr kevin mayo a html pdf dec   the ludwig institute and propharmaceuticals collaborate to test davanat®s ability to enhance the function of antitumor t lymphocytes newton mass december    propharmaceuticals inc otcprwp today announced that the brussels branch of the ludwig institute of cancer research is testing the ability of davanat® to stop galectin from blocking the immune system’s action on cancer cells peer reviewed studies have demonstrated that galectin and galectin html pdf dec   propharmaceuticals closes  tranche newton ma december   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date f html pdf nov   propharmaceuticals reports third quarter financial results newton ma – november   – propharmaceuticals inc otcbb prwp a developer of galectintargeted carbohydrate therapeutic compounds to treat cancer and fibrosis today reported its financial results for the third quarter and first nine months of fiscal  these results are included in the company’s quarterly report o html pdf nov   propharmaceuticals closes  tranche brings total to  million of  million private placement newton ma november   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date fr html pdf oct   propharmaceuticals closes  tranche brings total to  million of  million private placement newton ma october   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date to  html pdf sep   propharmaceuticals to present a corporate update at the maxim group growth conference newton mass september   propharmaceuticals inc otc prwp today announced that theodore zucconi phd chief executive officer and james czirr chairman of the board propharmaceuticals inc are scheduled to present a corporate update at the maxim group growth conference on september   at  pm at the grand hyatt h html pdf aug   propharmaceuticals to present a corporate update at the rodman  renshaw annual global investment conference newton mass august   propharmaceuticals inc otc prwp today announced that theodore zucconi phd chief executive officer and james czirr chairman of the board propharmaceuticals inc are scheduled to present a corporate update at the rodman  renshaw annual global investment conference on september   at  pm at th html pdf aug   propharmaceuticals appoints arthur r bobby greenberg to its board of directors newton ma – august   – propharmaceuticals inc otcbb prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today announced the appointment of arthur r “bobby” greenberg to its board of directors mr greenberg’s appointment brings the board to nine members html pdf aug   propharmaceuticals reports second quarter and first six months  financial results newton ma – august   – propharmaceuticals inc otcbb prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today announced the appointment of arthur r “bobby” greenberg to its board of directors mr greenberg’s appointment brings the board to nine members html pdf jul   court issues judgment dismissing trade secret lawsuit against propharmaceuticals newton ma july   – propharmaceuticals inc otcbb prwp “the company” today announced that the superior court of suffolk county in massachusetts formally issued its judgment yesterday dismissing the trade secret lawsuit prosecuted by prospect therapeutics inc “prospect” against the company and its f html pdf jul   propharmaceuticals prevails in trade secret lawsuit newton ma – july   – propharmaceuticals inc otcbb prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today announced that the suffolk county superior court allowed propharmaceuticals’ “the company” motion to dismiss the trade secret lawsuit prosecuted  html pdf jul   propharmaceuticals names noted physician dr gilbert s omenn to scientific advisory board newton ma – july   – propharmaceuticals inc otcbb prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancers and fibrosis today named dr gilbert s omenn to its scientific advisory board “my research in cancer biology and chemoprevention piqued my interests in p html pdf jul   propharmaceuticals closes  tranche brings total to  million of  million private placement newton ma july   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed a  tranche of a private placement of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants this tranche brings the total raised to date to  html pdf jun   propharmaceuticals chief scientist published articles in three prestigious peerreviewed journals newton ma – june   – propharmaceuticals inc otc prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today announced that its chief scientist and cofounder anatole klyosov phd published articles in the biochemical journal carbohydrate research and glycobiology that fu html pdf may   propharmaceuticals reports full year and fourth quarter  financial results newton mass march    propharmaceuticals inc otc prwpob a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today reported its full year and fourth quarter financial results for the period ended december   “we continue to make progress towards ou html pdf may   propharmaceuticals reports first quarter  financial results newton ma – may   – propharmaceuticals inc otcbb prwp a developer of carbohydratebased targeted therapeutic compounds to treat cancer and fibrosis today reported its financial results for the first quarter of fiscal  these results are included in the company’s quarterly report on form q for the threemonth html pdf apr   propharmaceuticals engages perceptive imagineering to market davanat® in central  south america newton ma – april   – propharmaceuticals inc otcbb prwp a biopharmaceutical company developing proprietary therapeutic compounds to treat cancer and fibrosis has entered into a consulting agreement with perceptive imagineering llc “perceptive” to represent the company in central and south america starti html pdf apr   propharmaceuticals davanat® prevents mucositis a serious side effect of chemotherapy in all  cancer patients treated newton mass april    propharmaceuticals inc otcbb prwpob today announced that a review of data from its phase i  ii clinical trials show that no mucositis serious adverse events saes were found in approximately  cancer patients that were treated with davanat® and chemotherapy that included fu for most cancer tre html pdf mar   propharmaceuticals licenses to procaps sa exclusive marketing and distribution rights to commercialize davanat® to treat cancer in colombia south america newton mass march    propharmaceuticals inc otc prwp a developer of therapeutics that target galectin receptors to treat cancer and fibrosis today announced that it has granted procaps sa exclusive rights to market and sell davanat® to treat cancer in colombia south america phase ll clinical trial results for latest html pdf feb   propharmaceuticals postpones rights offering newton ma february   propharmaceuticals inc otcbb prwp the company today announced that it has postponed its previously announced rights offering subject to market conditions the company will determine whether it will proceed with the rights offering after it files its annual report on form k with the securities and excha html pdf feb   propharmaceuticals closes initial  million tranche of up to  million private placement newton ma february   propharmaceuticals inc otcbb prwp the “company” today announced that it has closed the initial  million tranche of a private placement in the amount of up to  million with x fund lp which is purchasing unregistered series b convertible preferred stock and warrants  html pdf feb   propharmaceuticals names theodore d zucconi phd chief executive officer newton ma february   propharmaceuticals inc otcbb prwp “the company” today announced that theodore d zucconi phd a member of the company’s board of directors and former president was named chief executive officer and president dr zucconi replaces david platt phd who will become chief executive offi html pdf feb   propharmaceuticals updates rights offering files amended registration statement newton ma february   propharmaceuticals inc otcbb prwp today announced that it has filed an amended registration statement with the securities and exchange commission sec available at wwwsecgov for a rights offering to its shareholders and certain warrant holders collectively the “holders” and that the company ha html pdf page  view  results per page  results per page  results per page  add release to briefcase financial tear sheet download library shareholder briefcase   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information galectin therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports galectin therapeutics inc  product pipeline review   galectin therapeutics inc  product pipeline review   wgr  december  global  pages global markets direct description table of content sample report enquiry before buy related reports galectin therapeutics inc  product pipeline review  summaryglobal markets direct’s ‘galectin therapeutics inc  product pipeline review  ’ provides an overview of the galectin therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of galectin therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of galectin therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of galectin therapeutics inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the galectin therapeutics inc’s pipeline productsreasons to buy evaluate galectin therapeutics inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of galectin therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the galectin therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of galectin therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of galectin therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of galectin therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures galectin therapeutics inc snapshot galectin therapeutics inc overview key information key facts galectin therapeutics inc  research and development overview key therapeutic areas galectin therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy galectin therapeutics inc  pipeline products glance galectin therapeutics inc  clinical stage pipeline products phase i productscombination treatment modalities galectin therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities galectin therapeutics inc  drug profiles grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress grmd product description mechanism of action rd progress grmd product description mechanism of action rd progress polysaccharides to inhibit galectin for fibrosis inflammation and cancer product description mechanism of action rd progress galectin therapeutics inc  pipeline analysis galectin therapeutics inc  pipeline products by target galectin therapeutics inc  pipeline products by route of administration galectin therapeutics inc  pipeline products by molecule type galectin therapeutics inc  pipeline products by mechanism of action galectin therapeutics inc  recent pipeline updates galectin therapeutics inc  dormant projects galectin therapeutics inc  discontinued pipeline products discontinued pipeline product profiles gmct galectin therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesgalectin therapeutics inc key information galectin therapeutics inc key facts galectin therapeutics inc  pipeline by indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  phase i  galectin therapeutics inc  preclinical  galectin therapeutics inc  discovery  galectin therapeutics inc  pipeline by target  galectin therapeutics inc  pipeline by route of administration  galectin therapeutics inc  pipeline by molecule type  galectin therapeutics inc  pipeline products by mechanism of action  galectin therapeutics inc  recent pipeline updates  galectin therapeutics inc  dormant developmental projects galectin therapeutics inc  discontinued pipeline products  list of figuresgalectin therapeutics inc  pipeline by top  indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  pipeline by top  target  galectin therapeutics inc  pipeline by top  route of administration  galectin therapeutics inc  pipeline by top  molecule type  galectin therapeutics inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send market report galectin therapeutics inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing galectin therapeutics inc  product pipeline review   aug    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs galectin therapeutics inc  product pipeline review   provides an overview of the galectin therapeutics incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of galectin therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of galectin therapeutics inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of galectin therapeutics incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the galectin therapeutics incs pipeline productsreasons to get this reportevaluate galectin therapeutics incs strategic position with total access to detailed information on its product pipelineassess the growth potential of galectin therapeutics inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the galectin therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of galectin therapeutics inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of galectin therapeutics incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of galectin therapeutics inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures galectin therapeutics inc snapshot galectin therapeutics inc overview key information key facts galectin therapeutics inc  research and development overview key therapeutic areas galectin therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy galectin therapeutics inc  pipeline products glance galectin therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities galectin therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities galectin therapeutics inc  drug profiles grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress grmd product description mechanism of action rd progress galectin therapeutics inc  pipeline analysis galectin therapeutics inc  pipeline products by target galectin therapeutics inc  pipeline products by route of administration galectin therapeutics inc  pipeline products by molecule type galectin therapeutics inc  pipeline products by mechanism of action galectin therapeutics inc  recent pipeline updates galectin therapeutics inc  dormant projects galectin therapeutics inc  discontinued pipeline products discontinued pipeline product profiles gmct galectin therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesgalectin therapeutics inc key information galectin therapeutics inc key facts galectin therapeutics inc  pipeline by indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  phase ii  galectin therapeutics inc  phase i  galectin therapeutics inc  preclinical  galectin therapeutics inc  discovery  galectin therapeutics inc  pipeline by target  galectin therapeutics inc  pipeline by route of administration  galectin therapeutics inc  pipeline by molecule type  galectin therapeutics inc  pipeline products by mechanism of action  galectin therapeutics inc  recent pipeline updates  galectin therapeutics inc  dormant developmental projects galectin therapeutics inc  discontinued pipeline products  list of figuresgalectin therapeutics inc  pipeline by top  indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  pipeline by top  target  galectin therapeutics inc  pipeline by top  route of administration  galectin therapeutics inc  pipeline by top  molecule type  galectin therapeutics inc  pipeline products by top  mechanism of action   companies mentioned in this reportgalectin therapeutics inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc galectin therapeutics inc  product pipeline review      about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing you are here home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure research and markets orders department was very responsive and helpful thank you for making this a great purchase experience read more ms keiko tokuda marketing manager eventbrite galectin therapeutics inc  product pipeline review   id  company profile august   pages global markets direct galectin therapeutics inc description table of contents samples formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend galectin therapeutics inc  product pipeline review  summarythe report ‘galectin therapeutics inc  product pipeline review  ’ provides an overview of the galectin therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of galectin therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsthe report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profilesrecords featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of galectin therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of galectin therapeutics inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the galectin therapeutics inc’s pipeline productsreasons to buy evaluate galectin therapeutics inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of galectin therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the galectin therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of galectin therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of galectin therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of galectin therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues show less read more note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend list of tables list of figures galectin therapeutics inc snapshot galectin therapeutics inc overview key information key facts galectin therapeutics inc  research and development overview key therapeutic areas galectin therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy galectin therapeutics inc  pipeline products glance galectin therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities galectin therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities galectin therapeutics inc  drug profiles grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress grmd product description mechanism of action rd progress galectin therapeutics inc  pipeline analysis galectin therapeutics inc  pipeline products by target galectin therapeutics inc  pipeline products by route of administration galectin therapeutics inc  pipeline products by molecule type galectin therapeutics inc  pipeline products by mechanism of action galectin therapeutics inc  recent pipeline updates galectin therapeutics inc  dormant projects galectin therapeutics inc  discontinued pipeline products discontinued pipeline product profiles gmct galectin therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesgalectin therapeutics inc key information galectin therapeutics inc key facts galectin therapeutics inc  pipeline by indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  phase ii  galectin therapeutics inc  phase i  galectin therapeutics inc  preclinical  galectin therapeutics inc  discovery  galectin therapeutics inc  pipeline by target  galectin therapeutics inc  pipeline by route of administration  galectin therapeutics inc  pipeline by molecule type  galectin therapeutics inc  pipeline products by mechanism of action  galectin therapeutics inc  recent pipeline updates  galectin therapeutics inc  dormant developmental projects galectin therapeutics inc  discontinued pipeline products  list of figuresgalectin therapeutics inc  pipeline by top  indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  pipeline by top  target  galectin therapeutics inc  pipeline by top  route of administration  galectin therapeutics inc  pipeline by top  molecule type  galectin therapeutics inc  pipeline products by top  mechanism of action  note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products glycomimetics inc  product pipeline review    company profile august  from €eurusd£gbp insys therapeutics inc  product pipeline review    company profile april  from €eurusd£gbp sarepta therapeutics inc  product pipeline review    company profile june  from €eurusd£gbp tobira therapeutics inc  product pipeline review    company profile june  from €eurusd£gbp halozyme therapeutics inc  product pipeline review    company profile may  region global from €eurusd£gbp argos therapeutics inc  product pipeline review    company profile august  from €eurusd£gbp heron therapeutics inc  product pipeline review    company profile august  from €eurusd£gbp mersana therapeutics inc  product pipeline review    company profile september  from €eurusd£gbp arno therapeutics inc  product pipeline review    company profile august  from €eurusd£gbp aestus therapeutics inc  product pipeline review    company profile march  from €eurusd£gbp close galectin therapeutics inc  product pipeline review   close ask a question required information product galectin therapeutics inc  product pipeline review   your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change galectin therapeutics inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › galectin therapeutics inc print share galectin therapeutics inc address galectin therapeutics inc  peachtree industrial boulevard suite  norcross georgia contact detailsphone  website galectintherapeuticscom latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide galectin therapeutics nasdaq galt home about galectin our team our pipeline news investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs contact us contact us home » contact us galectin therapeutics street address  peachtree industrial boulevardsuite norcross georgia  click here for driving directions phone  fax  personal information contact information your message all fields are required   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information galectin therapeutics inc  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail galectin therapeutics inc  product pipeline review   published august  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets direct’s ‘galectin therapeutics inc  product pipeline review ’ provides an overview of the galectin therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of galectin therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of galectin therapeutics inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of galectin therapeutics inc’s human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the galectin therapeutics inc’s pipeline productsreasons to buyevaluate galectin therapeutics inc’s strategic position with total access to detailed information on its product pipelineassess the growth potential of galectin therapeutics inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the galectin therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of galectin therapeutics inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of galectin therapeutics incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of galectin therapeutics inc and identify potential opportunities in those areasavoid intellectual property rights related issues galectin therapeutics inc  product pipeline review   table of contentstable of contents list of tables list of figures galectin therapeutics inc snapshot galectin therapeutics inc overview key information key facts galectin therapeutics inc  research and development overview key therapeutic areas galectin therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy galectin therapeutics inc  pipeline products glance galectin therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities galectin therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities galectin therapeutics inc  drug profiles grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress gmct product description mechanism of action rd progress grmd product description mechanism of action rd progress grmd product description mechanism of action rd progress galectin therapeutics inc  pipeline analysis galectin therapeutics inc  pipeline products by target galectin therapeutics inc  pipeline products by route of administration galectin therapeutics inc  pipeline products by molecule type galectin therapeutics inc  pipeline products by mechanism of action galectin therapeutics inc  recent pipeline updates galectin therapeutics inc  dormant projects galectin therapeutics inc  discontinued pipeline products discontinued pipeline product profiles gmct galectin therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesgalectin therapeutics inc key information galectin therapeutics inc key facts galectin therapeutics inc  pipeline by indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  phase ii  galectin therapeutics inc  phase i  galectin therapeutics inc  preclinical  galectin therapeutics inc  discovery  galectin therapeutics inc  pipeline by target  galectin therapeutics inc  pipeline by route of administration  galectin therapeutics inc  pipeline by molecule type  galectin therapeutics inc  pipeline products by mechanism of action  galectin therapeutics inc  recent pipeline updates  galectin therapeutics inc  dormant developmental projects galectin therapeutics inc  discontinued pipeline products  list of figuresgalectin therapeutics inc  pipeline by top  indication  galectin therapeutics inc  pipeline by stage of development  galectin therapeutics inc  monotherapy products in pipeline  galectin therapeutics inc  pipeline by top  target  galectin therapeutics inc  pipeline by top  route of administration  galectin therapeutics inc  pipeline by top  molecule type  galectin therapeutics inc  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports global bcg vaccine detailed analysis report  this report splits bcg vaccine by drug types end users this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product global tinnitus drug market professional survey report  this report studies tinnitus drug in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  th global transdermal skin patches market professional survey report  this report studies transdermal skin patches in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global proton pump inhibitors ppis market professional survey report  this report studies proton pump inhibitors ppis in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecas global nonopioid pain patches market professional survey report  this report studies nonopioid pain patches in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global wound cleanser products market professional survey report  this report studies wound cleanser products in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  asiapacific sodium hyaluronate market report  in this report the asiapacific sodium hyaluronate market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacif asiapacific sialic acid market report  in this report the asiapacific sialic acid market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into asiapacific nerve repair biomaterial market report  in this report the asiapacific nerve repair biomaterial market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asia asiapacific lipoic acid market report  in this report the asiapacific lipoic acid market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports management  galectin therapeutics inc contact us investor relations overview press releases events  presentations corporate governance management board of directors committee composition financial information sec filings annual reports quarterly reports stock information historic stock lookup analyst coverage faqs newsroom home who we are what we do who we help overview press releases events  presentations corporate governance management board of directors committee composition financial information stock information faqs email alert subscription management home » investor relations » corporate governance » management peter g traber md president chief executive officer and chief medical officer dr traber is president emeritus of baylor college of medicine where he was chief executive officer from  to  from  to  he was senior vice president of clinical development and medical affairs and chief medical officer of glaxosmithkline plc dr traber served as chief executive officer of the university of pennsylvania health system and was chair of the department of internal medicine and chief of gastroenterology for the university of pennsylvania school of medicine dr traber has also managed a molecular biology research laboratory and published over  articles of original research reviews and book chapters dr traber received his md from wayne state school of medicine a bs in chemical engineering from the university of michigan and a certificate in medical leadership from wharton business school harold h shlevin phd chief operating officer and corporate secretary dr shlevin is a bioscience industry executive with  years of senior management experience in the development and commercialization of pharmaceuticals diagnostics and vaccines before joining galectin therapeutics dr shlevin led georgia institute of technology’s advanced technology development center atdc as principal and manager of bioscience commercialization efforts where he served as a catalyst for new bioscience startup companies his leadership roles have included president and chief executive officer of solvay pharmaceuticals where he oversaw the successful launch of the first topical testosterone gel product in the us cofounder of ciba vision ophthalmics a specialty ophthalmic drug company where he headed efforts leading to the approval of the first nonsteroidal agent for treatment of ocular inflammation and several other drug products founder president and chief executive officer of tikvah therapeutics a company focused on clinical development of therapeutics for treatment of neurological diseases and vice president and head of operations and commercial development for altea therapeutics corporation a clinicalstage drug delivery company with platform technology applicable to the transdermal delivery of biologics dr shlevin earned his ba from boston university and ms and phd in physiology from the university of rochester medical school he completed postdoctoral training in pharmacology at mayo clinic where he subsequently served as assistant professor of pharmacology and physiology he is a member of scientific and business societies including the institute of electrical and electronics engineers licensing executives society american physiological society american society of pharmacology and experimental therapeutics and is an inventor on several issued and pending patents dr shlevin currently serves on the board of directors of cardiome pharma corp nasdaqcrme and as an advisor to clearside biomedical inc jack w callicutt cpa chief financial officer mr callicutt has over  years of public and private company experience including more than a decade of audit tax and sec registrant experience with a major accounting firm he was most recently chief financial officer for reach health inc a telemedicine firm where he completed a  million private placement previous positions include chief financial officer of vystar corporation a public medical device company whose latex products are devoid of antigenic proteins where he led all areas of financial reporting accounting treasury risk management and administration and secured over  million in financing previous experiences also include chief financial officer roles at private companies including ivox and tikvah therapeutics and at coratus genetics a publiclytraded biopharmaceutical company mr callicutt is a certified public accountant and graduated cum laude with a bba degree in accounting and computer science from delta state university rex horton executive director of regulatory affairs and quality assurance mr horton is an experienced industry professional with  years of management and leadership experience in global regulatory affairs matters including drugs biologics and vaccines he has broad range of regulatory affairs and quality leadership experience that is directly relevant to galectin therapeutics’ development programs with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas including gastroenterology he was most recently was director of regulatory affairs at chelsea therapeutics where he successfully led the organization through its first nda filing and favorable fda advisory committee meeting in past leadership roles at solvay pharmaceuticals and abbott laboratories he led approval efforts for key products including androgel® stickpack creon® capsules and luvox® cr capsules he has also provided chemistry manufacturing and controls cmc regulatory leadership and support of inds and ndas including estrogel® and androgel® pump mr horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by solvay in its interactions with the fda he earned his bachelor’s degree in industrialmanufacturing and systems engineering from the georgia institute of technology he is a member of the regulatory affairs professional society raps drug information association dia and american association of pharmaceutical scientists aaps adam e allgood pharmd rph executive director of clinical development dr allgood is an experienced industry professional with more than  years of pharmaceutical industry experience in effectively designing implementing monitoring and directing clinical programs in all four phases of clinical development ranging from phase  firstinhuman trials to large global phase  clinical trials and post marketing trials his therapeutic expertise spans a variety of therapeutic areas including gastroenterology and encompasses clinical trial leadership key opinion leader interface significant contract research organization management experience clinical trial investigator training and clinical advisory board responsibilities in addition dr allgood has extensive clinical research andor regulatory experience in immunology rheumatology neurology and women’s health dr allgood most recently was associate director of global pharmaceutical regulatory affairs at ucb inc a multinational biopharmaceutical company his prior positions include leadership roles at abbott laboratories and solvay pharmaceuticals in regulatory affairs clinical development and medical affairs dr allgood earned his doctor of pharmacy pharmd degree summa cum laude from mercer university college of pharmacy and health sciences in atlanta and is a registered pharmacist rph he is a member of the american pharmacists association apha the georgia pharmacy association gpha and the association of the united states army ausa eliezer zomer phd vice president discovery research and product development dr zomer is the founder of alicon biological control where he served from  to  he was vice president of product development at safescience inc from  to  and from  to  was vice president of research and development at charm sciences inc dr zomer received a bsc degree in industrial microbiology from the university of tel aviv a phd in biochemistry from the university of massachusetts in  and completed his postdoctoral study at the national institutes of health financial tear sheet download library shareholder briefcase   galectin therapeutics inc  all rights reserved privacy policy  terms of use  site map disclaimer this site may contain forwardlooking information galt profile  galectin therapeutics inc stock  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health caregalectin therapeutics inc galtnasdaqcm  nasdaqcm delayed price currency in usdadd to watchlist at close pm edt  after hours pm edtpeople also watchcnatocrxgaleevokglmdsummaryconversationsstatisticsprofilefinancialsoptionsholdershistorical dataanalystsgalectin therapeutics inc peachtree industrial boulevardsuite norcross ga united stateshttpwwwgalectintherapeuticscomsector healthcareindustry drugs  genericfull time employees key executivesnametitlepayexercisedagedr peter g traber mdchief exec officer pres chief medical officer  directorknamr jack w callicutt cpachief financial officerknadr harold h shlevin phdcoo  corp secknadr eliezer zomer phdvp of discovery research and product develnanamr steven schubertvp of finnananaamounts are as of december   and compensation values are for the last fiscal year ending on that date pay is salary bonuses etc exercised is the value of options exercised during the fiscal year currency in usddescriptiongalectin therapeutics inc a clinical stage biopharmaceutical company engages in the research and development of therapies for fibrotic disease and cancer the companys lead product candidate includes galectin inhibitor grmd a galactoarabinorhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in nonalcoholic steatohepatitis patients as well as for the treatment of cancer it also engages in developing gmct which is in preclinical development state for the treatment of cardiac and vascular fibrosis as well as focuses on developing grmd for the treatment of psoriasis the company through its collaborative joint venture galectin sciences llc with sbh sciences inc is also involved in the research and development of small organic molecule inhibitors of galectin for oral administration the company was formerly known as propharmaceuticals inc and changed its name to galectin therapeutics inc in may  galectin therapeutics inc was founded in  and is based in norcross georgiacorporate governancegalectin therapeutics inc’s iss governance qualityscore as of na is na the pillar scores are audit na board na shareholder rights na compensation nacorporate governance scores courtesy of institutional shareholder services iss scores indicate decile rank relative to index or region a decile score of  indicates lower governance risk while a  indicates higher governance riskyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated galectin therapeutics inc galt  medical equipment  deals and alliances profile by globaldata market research report at marketreportsonlinecom welcome guest  register  login      salesmarketreportsonlinecom home  company profiles  report detail galectin therapeutics inc galt  medical equipment  deals and alliances profile report description table of contents faqs summary galectin therapeutics inc galectin therapeutics formerly propharmaceuticals inc is a biotechnology company that discovers develops and commercializes therapies for fibrotic disease and cancer the companys products comprise grmd and gmct its grmd is a drug candidate used for treating fibrotic liver disease its gmct is a vaccine used to treat patients with advanced melanoma a deadly skin cancer galectin therapeutics offers research and study of science of galectin proteins the companys products are used to treat fibrosis galectin effects on liver fibrosis lung fibrosis and others galectin therapeutics is headquartered in norcross georgia the us galectin therapeutics inc galt  medical equipment  deals and alliances profile provides you comprehensive data and trend analysis of the companys mergers and acquisitions mas partnerships and financings the report provides detailed information on mergers and acquisitions equitydebt offerings private equity venture financing and partnership transactions recorded by the company over a five year period the report offers detailed comparative data on the number of deals and their value categorized into deal types subsector and regions globaldata derived the data presented in this report from proprietary inhouse medical etrack deals database and primary and secondary research scope  financial deals  analysis of the companys financial deals including mergers and acquisitions equitydebt offerings private equity venture financing and partnerships  deals by year  chart and table displaying information encompassing the number of deals and value reported by the company by year for a five year period  deals by type  chart and table depicting information including the number of deals and value reported by the company by type such as mergers and acquisitions equitydebt offering etc  deals by region  chart and table presenting information on the number of deals and value reported by the company by region which includes north america europe asia pacific the middle east and africa and south and central america  deals by subsector  chart and table showing information on the number of deals and value reported by the company by subsector  major deals  information on the companys major financial deals each such deal has a brief summary deal type deal rationale and deal financials and target companys major public companies key financial metrics and ratios  business description  a brief description of the companys operations  key employees  a list of the key executives of the company  important locations and subsidiaries  a list and contact details of key centers of operation and subsidiaries of the company  key competitors  a list of the key competitors of the company  key recent developments  a brief on recent news about the company reasons to buy get detailed information on the companys financial deals that enable you to understand the companys expansiondivestiture and fund requirements  the profile enables you to analyze the companys financial deals by region by year by business segments and by type for a five year period understand the companys business segments expansion  divestiture strategy  the profile presents deals from the companys core business segments perspective to help you understand its corporate strategy access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company  detailed information on major recent deals includes a summary of each deal deal type deal rationale deal financials and target companys key financial metrics and ratios equip yourself with detailed information about the companys operations to identify potential customers and suppliers  the profile analyzes the companys business structure locations and subsidiaries key executives and key competitors stay uptodate on the major developments affecting the company  recent developments concerning the company presented in the profile help you track important events gain key insights into the company for academic or business research  key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs note some sections may be missing if data is unavailable for the company single user license report will be emailed in pdf format and can be accessed by a specific user this license type allows the report to be printed site license report will be emailed in pdf and  allows only employees within the same geographical location within the organization to access it this license type allows the report to be printed global site license report will be emailed in pdf format and allows all employees within the organization to access it  this license type allows the report to be printed why httpwwwmarketreportsonlinecom galectin therapeutics inc galt  medical equipment  deals and alliances profile published by globaldata price single user license us   site license us   global site license us   how to purchase purchase reports from our site in few easy clicks please follow the description given below to complete your purchase process step  select the report title of your interest and click on buy now button next to the price option step  you will arrive at the purchase page where you will be requested to signup new user or login registered user please note that inkeeping with the security check on the website you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information step  after signuplogin you will arrive at our payment page on paypal you will see your order summary as well as an option to choose a way to pay select a payment option from pay with a paypal account or pay with a debit or credit card marketreportonline accepts visa mastercard american express and discover through paypal fill up the required details in the option of your choice step  once you follow the required process in step  as mentioned above you have successfully completed the purchase process step  once you have successfully completed the purchase process you will receive a confirmation email the report will then be emailed to you directly by the publisher as per our agreement with the publisher for orders that are placed after working hours the delivery of the reports will be made on the next business day for orders that are placed during weekends the delivery of the reports will be made on the next working business day please note if you select purchase by invoice you will receive your report only once the payment has been received if you have any queries about how to order please contact us price  single user license us   site license us   global site license us   published jul  no of pages  subscription option using our subscription option you get access to market research reports and industry data of company profiles market as per your needs get the best of company profiles research reports by utilizing your research budgets in an optimum way contact salesmarketreportsonlinecom for details email alert get email alerts about market research reports from industries and publishers of your interest market insights top banking trends the current trend include some of the key trends from last year with new trends in the areas of customer experience digital and mobile delivery digital payments innovation alternative products auth global tea market propelled by high green and black tea demands tea is the most popular beverages consumed globally the biggest share of tea consumption is mostly local in the country or region of production the tea industry is characterized by a few corporations monitoring the comp telehealth is the biggest revolution in healthcare telehealth is a very effectual way to consume medical care and it is bound for growth over time telehealth services expenditure in the us is estimated to catapult nearly ten times in the coming years forecasts are that